Cargando…

Approaches to the Management of Agents Used for the Treatment of Multiple Sclerosis: Consensus Statements from a Panel of U.S. Managed Care Pharmacists and Physicians

BACKGROUND: Multiple sclerosis (MS) is a chronic, disabling, and costly disease with several treatment options available; however, there is variability in evidence-based clinical guidelines. Therefore, payers are at a disadvantage when making management decisions without the benefit of definitive gu...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, Ross M., Happe, Laura E., Meyer, Kellie L., Spear, Rachel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437556/
https://www.ncbi.nlm.nih.gov/pubmed/22235955
http://dx.doi.org/10.18553/jmcp.2012.18.1.54
_version_ 1785092553251487744
author Miller, Ross M.
Happe, Laura E.
Meyer, Kellie L.
Spear, Rachel J.
author_facet Miller, Ross M.
Happe, Laura E.
Meyer, Kellie L.
Spear, Rachel J.
author_sort Miller, Ross M.
collection PubMed
description BACKGROUND: Multiple sclerosis (MS) is a chronic, disabling, and costly disease with several treatment options available; however, there is variability in evidence-based clinical guidelines. Therefore, payers are at a disadvantage when making management decisions without the benefit of definitive guidance from treatment guidelines. OBJECTIVES: To outline approaches for the management of agents used to treat MS, as determined from a group of U.S. managed care pharmacists and physicians. METHODS: A modified Delphi process was used to develop consensus statements regarding MS management approaches. The panel was composed of experts in managed care and included 8 pharmacy directors and 6 medical directors presently or previously involved in formulary decision making from 12 health plans, 1 specialty pharmacy, and 1 consulting company. These decision makers, who have experience designing health care benefits that include MS treatments, provided anonymous feedback through 2 rounds of web-based surveys and participated in 1 live panel meeting held in December 2010. Consensus was defined as a mean response of at least 3.3 or 100% of responses either “agree” or “strongly agree” (i.e., no panelist answered “disagree” or “strongly disagree”) on a 4-item Likert scale (1 = strongly disagree, 2 = disagree, 3 = agree, 4 = strongly agree). RESULTS: After 3 phases, these managed care representatives reached consensus on 25 statements for management of patients with MS. Consistent with managed care principles, this group of managed care experts found that health plans should consider efficacy, effectiveness, and safety, as well as patient preference, when evaluating MS therapies for formulary placement. Cost and contracting should be considered if efficacy and safety are judged to be comparable between agents. CONCLUSIONS: The consensus statements developed by a panel of managed care representatives provide some insight into decision making in formulary and utilization management of MS therapies.
format Online
Article
Text
id pubmed-10437556
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Academy of Managed Care Pharmacy
record_format MEDLINE/PubMed
spelling pubmed-104375562023-08-21 Approaches to the Management of Agents Used for the Treatment of Multiple Sclerosis: Consensus Statements from a Panel of U.S. Managed Care Pharmacists and Physicians Miller, Ross M. Happe, Laura E. Meyer, Kellie L. Spear, Rachel J. J Manag Care Pharm Contemporary Subject BACKGROUND: Multiple sclerosis (MS) is a chronic, disabling, and costly disease with several treatment options available; however, there is variability in evidence-based clinical guidelines. Therefore, payers are at a disadvantage when making management decisions without the benefit of definitive guidance from treatment guidelines. OBJECTIVES: To outline approaches for the management of agents used to treat MS, as determined from a group of U.S. managed care pharmacists and physicians. METHODS: A modified Delphi process was used to develop consensus statements regarding MS management approaches. The panel was composed of experts in managed care and included 8 pharmacy directors and 6 medical directors presently or previously involved in formulary decision making from 12 health plans, 1 specialty pharmacy, and 1 consulting company. These decision makers, who have experience designing health care benefits that include MS treatments, provided anonymous feedback through 2 rounds of web-based surveys and participated in 1 live panel meeting held in December 2010. Consensus was defined as a mean response of at least 3.3 or 100% of responses either “agree” or “strongly agree” (i.e., no panelist answered “disagree” or “strongly disagree”) on a 4-item Likert scale (1 = strongly disagree, 2 = disagree, 3 = agree, 4 = strongly agree). RESULTS: After 3 phases, these managed care representatives reached consensus on 25 statements for management of patients with MS. Consistent with managed care principles, this group of managed care experts found that health plans should consider efficacy, effectiveness, and safety, as well as patient preference, when evaluating MS therapies for formulary placement. Cost and contracting should be considered if efficacy and safety are judged to be comparable between agents. CONCLUSIONS: The consensus statements developed by a panel of managed care representatives provide some insight into decision making in formulary and utilization management of MS therapies. Academy of Managed Care Pharmacy 2012-01 /pmc/articles/PMC10437556/ /pubmed/22235955 http://dx.doi.org/10.18553/jmcp.2012.18.1.54 Text en Copyright © 2012, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Contemporary Subject
Miller, Ross M.
Happe, Laura E.
Meyer, Kellie L.
Spear, Rachel J.
Approaches to the Management of Agents Used for the Treatment of Multiple Sclerosis: Consensus Statements from a Panel of U.S. Managed Care Pharmacists and Physicians
title Approaches to the Management of Agents Used for the Treatment of Multiple Sclerosis: Consensus Statements from a Panel of U.S. Managed Care Pharmacists and Physicians
title_full Approaches to the Management of Agents Used for the Treatment of Multiple Sclerosis: Consensus Statements from a Panel of U.S. Managed Care Pharmacists and Physicians
title_fullStr Approaches to the Management of Agents Used for the Treatment of Multiple Sclerosis: Consensus Statements from a Panel of U.S. Managed Care Pharmacists and Physicians
title_full_unstemmed Approaches to the Management of Agents Used for the Treatment of Multiple Sclerosis: Consensus Statements from a Panel of U.S. Managed Care Pharmacists and Physicians
title_short Approaches to the Management of Agents Used for the Treatment of Multiple Sclerosis: Consensus Statements from a Panel of U.S. Managed Care Pharmacists and Physicians
title_sort approaches to the management of agents used for the treatment of multiple sclerosis: consensus statements from a panel of u.s. managed care pharmacists and physicians
topic Contemporary Subject
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437556/
https://www.ncbi.nlm.nih.gov/pubmed/22235955
http://dx.doi.org/10.18553/jmcp.2012.18.1.54
work_keys_str_mv AT millerrossm approachestothemanagementofagentsusedforthetreatmentofmultiplesclerosisconsensusstatementsfromapanelofusmanagedcarepharmacistsandphysicians
AT happelaurae approachestothemanagementofagentsusedforthetreatmentofmultiplesclerosisconsensusstatementsfromapanelofusmanagedcarepharmacistsandphysicians
AT meyerkelliel approachestothemanagementofagentsusedforthetreatmentofmultiplesclerosisconsensusstatementsfromapanelofusmanagedcarepharmacistsandphysicians
AT spearrachelj approachestothemanagementofagentsusedforthetreatmentofmultiplesclerosisconsensusstatementsfromapanelofusmanagedcarepharmacistsandphysicians